Is Eiko Lifescience overvalued or undervalued?

As of 20 October 2025, Eiko Lifescience's valuation grade has moved from expensive to fair, indicating a shift in market perception. The company is currently fairly valued. Key ratios include a PE ratio of 37.87, an EV to EBITDA of 32.38, and a PEG ratio of 0.61, which suggests that the stock may be more attractive relative to its growth potential compared to its peers.
In comparison to its industry peers, Eiko Lifescience's PE ratio is slightly lower than Bajaj Finance's 38.6, which is categorized as very expensive, while Life Insurance, which is very attractive, has a significantly lower PE of 11.57. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 7.97%, reinforcing the notion that the stock may be undervalued in the current market context.